About

Solutions

Pipeline

Resources

Careers

Contact us

About

Solutions

Pipeline

Resources

Careers

Contact us

Forward-thinking biotech company, founded in 2023

Forward-thinking biotech companyfounded in 2023

Jump to link

Who we are

What we do

How we do it

Why we do it

Who we are

Innovating for a healthier future

At Mirai, we believe that everyone deserves access to effective and safe treatments for various diseases. Our primary goal is to contribute to tackling diseases that are traditionally challenging to treat due to various reasons, such as limited drug access or high toxicity, by empowering nanovehicles. We are committed to developing innovative solutions that can help improve the quality of life for patients worldwide.

Dr. Ryad HADJ HABIB

Dr. Ryad
HADJ HABIB

CEO, MIRAI Therapeutics

Doctor of Pharmacy & Serial Entrepreneur
#Thromboinflammation #Hemocompatibility #Nanovehicles

Doctor of Pharmacy

Serial Entrepreneur

Pr. Kheir Eddine KERBOUA

CSO, MIRAI Therapeutics

Immunology Unit,

Military University Hospital

Pr. Kheir Eddine KERBOUA

CSO, MIRAI Therapeutics

Immunology Unit, Military University Hospital of Oran
#Complementsystem #oxydative stress #Immunology

What we do

Mirai is a biotechnology company that specializes in creating novel solutions for targeted drug delivery and thromboinflammation. We aim to transform the field of biomedicine by improving the effectiveness of therapeutic treatments for various challenging diseases.

How we do it

Innovative solutions for targeted drug delivery

Innovative solutions for targeted drug delivery

Our innovative approach involves combining nanovehicles with drugs and our flagship product to provide precise and efficient drug delivery to specific target sites within the body while mitigating the risk of thromboinflammation.

Our innovative approach involves combining nanovehicles with drugs and our flagship product to provide precise and efficient drug delivery to specific target sites within the body while mitigating the risk of thromboinflammation.

This service provides valuable insights to researchers, pharmaceutical companies, and medical practitioners who are interested in understanding and managing the risks associated with introducing nanovehicles into the bloodstream.

Reduction of Thromboinflammation

Evaluation of thromboinflammation

Our invention: a polypeptide-based complement C3/C5 convertase inhibitor.

This service provides valuable insights to researchers, pharmaceutical companies, and medical practitioners who are interested in understanding and managing the risks associated with introducing nanovehicles into the bloodstream.

Why We Do It

Innovating for a healthier future

At Mirai, we believe that everyone deserves access to effective and safe treatments for various diseases. Our primary goal is to contribute to tackling diseases that are traditionally challenging to treat due to various reasons, such as limited drug access or high toxicity, by empowering nanovehicles. We are committed to developing innovative solutions that can help improve the quality of life for patients worldwide.

Take the next step with MIRAI

Copyright © Mirai Biotech 2023. All Rights Reserved.

Copyright © Mirai Biotech 2023. All Rights Reserved.